WO2015158031A1 - 用于毕赤酵母重组质粒和表达耐辐射球菌ppri蛋白的毕赤酵母重组菌的dna分子 - Google Patents

用于毕赤酵母重组质粒和表达耐辐射球菌ppri蛋白的毕赤酵母重组菌的dna分子 Download PDF

Info

Publication number
WO2015158031A1
WO2015158031A1 PCT/CN2014/078900 CN2014078900W WO2015158031A1 WO 2015158031 A1 WO2015158031 A1 WO 2015158031A1 CN 2014078900 W CN2014078900 W CN 2014078900W WO 2015158031 A1 WO2015158031 A1 WO 2015158031A1
Authority
WO
WIPO (PCT)
Prior art keywords
pichia pastoris
seq
dna molecule
protein
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/078900
Other languages
English (en)
French (fr)
Inventor
杨占山
吴伟
乔惠萍
文玲
施怡
任丽丽
于冬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou University
Original Assignee
Suzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou University filed Critical Suzhou University
Priority to US15/123,757 priority Critical patent/US10000761B2/en
Publication of WO2015158031A1 publication Critical patent/WO2015158031A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • the invention relates to the field of biotechnology, and particularly relates to a DNA molecule and a Pichia recombinant plasmid and a Pichia recombinant strain which efficiently expresses the P. aeruginosa Pprl protein.
  • Deinococcus radiodurans is the most radiation-resistant prokaryotic bacteria found on the earth to date. Its strong radiation resistance is related to its own sophisticated and efficient DNA repair system. Its proteins play a crucial role in their specific radiation resistance.
  • White et al. first published the gene sequence of DR bacteria, in which the inducer of pleiotropic proteins promoting DNA repair (?/?r/) is one of the radiation-resistant cocci.
  • a radiation-resistant gene with important regulatory functions which contains 987 bp and encodes 328 AA. Its product Pprl protein is encoded by DR-0167 and has a molecular weight of 37 KD.
  • pprl gene is the total switch gene for DNA repair and protection of radiation-resistant cocci
  • Pprl protein regulates the up-regulation of more than 210 genes through multiple signaling pathways, including 21 and DNA repair. And replication-related genes [H Lu, H Chen, G Xu, et al. DNA Repair, 2012, ll(2): 139-145].
  • Radiation-resistant cocci have been discovered for more than 50 years, researchers from all over the world Intensive research has been carried out on the gene and protein function of the radiation-resistant cocci. However, to date, these studies have been limited to prokaryotic cells, namely, the radiation-resistant cocci themselves or E. coli.
  • the Chinese patent No. 200910003512.2 first constructed a radiation-resistant cocci; the eukaryotic expression recombinant plasmid pCMV-HA-/?pr/ of the pr/ gene, which was transferred into human embryonic kidney 293T cells and irradiated mammals.
  • the successful expression of Pprl protein has a very significant preventive effect on lethal acute radiation injury in animals, indicating that Pprl protein is expected to be a new biological agent for the prevention and treatment of acute radiation injury.
  • the patent eukaryotic expression recombinant plasmid pCMV-HA-/?pr/ is currently difficult to obtain a highly efficient expression and purification of Pprl protein by human cell engineering.
  • Yeast is one of the eukaryotic expression systems commonly used in genetic engineering, of which Pichia pastoris
  • yeast pastoris is a kind of yeast engineering bacteria that uses sterol as the sole carbon source.
  • the yeast has the following advantages: 1.
  • the yeast is simple in genetic operation, the genome is highly stable, and the foreign gene can be expressed at a high level; 2.
  • the expression vector does not contain the yeast origin of replication.
  • the foreign gene is homologously recombined into the chromosome of the yeast cell, and the integrated foreign gene can be stably passaged with the growth of the yeast.
  • the P. aeruginosa Pprl protein can be purified by the expression of the eukaryotic expression system Pichia pastoris, the defects of Pprl protein expression by human cell or prokaryotic expression system E. coli expression in the prior art will be improved or solved.
  • Radiation-resistant cocci are prokaryotes, which differ greatly from the eukaryotic Pichia pastoris in terms of germline evolution, such as gene and protein composition and function, and protein amino acid codon preference. Therefore, if the P. radiodurans pprl gene is directly constructed into the Pichia pastoris expression system by genetic engineering, pre-experimental studies have confirmed that it is impossible and not conducive to the efficient expression of the P.
  • the present invention provides a technique for successfully expressing and purifying the Pprl protein of Deinococcus radiodurans Rl by the eukaryotic expression system Pichia pastoris, and lays a solid foundation for further research on the function, mechanism and application of the protein, and fills up the gap. There is no gap in the field of international radiation injury treatment and protection against prokaryotic protein drugs. The research on original protein drugs for radiation protection agents ranks first in the world. Summary of the invention
  • the present invention provides a recombinant plasmid comprising the DNA molecule and a recombinant Pichia recombinant strain which efficiently expresses the P. aeruginosa Pprl protein, which are also capable of achieving the object of the present invention.
  • the present invention provides the following technical solutions:
  • a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 1.
  • the invention optimizes and transforms the open reading frame (ORF) sequence of the pprl gene (DR O 167 , Gene ID: 1798483) of the bacterium D. cerevisiae (DR O 167 , Gene ID: 1798483) while keeping the amino acid sequence of the Pprl protein unchanged. , encoding a new synthetic; pr / gene, the nucleotide sequence shown in SEQ ID NO: 1, to distinguish the original; ? pr / gene, the nucleotide sequence shown in SEQ ID ⁇ : 1 is named Pi- Pprl.
  • the DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 1 of the present invention means that a sequence which facilitates isolation of a purified protein such as a 6 His tag sequence can be added in addition to the nucleotide sequence shown in SEQ ID NO: 1.
  • a sequence which facilitates isolation of a purified protein such as a 6 His tag sequence
  • Those skilled in the art will be able to utilize the prior art to link these sequences that do not affect the normal expression of the Pi-pprl gene to the Pi-pprl gene sequence, which is achievable to the skilled person.
  • one skilled in the art can add a corresponding restriction site at both ends of the DNA molecule according to the restriction site of the plasmid to be inserted, and other suitable tag sequences can be selected, which are not limited to the present invention.
  • the 6 X His tag sequence which can be implemented by the prior art after the present invention provides a key gene sequence, does not go beyond the core technical scope of the present invention.
  • the nucleotide sequence shown by SEQ ID NO: 1 is represented by the nucleus of SEQ ID NO: 2-41 Primers for the nucleotide sequence were obtained by Overlapping PCR amplification.
  • the present invention utilizes the overlapping portion of a series of overlapping (OVERLAP) primers (hereinafter referred to as p-1 to p-40) of the nucleotide sequence shown in SEQ ID NO: 24-1 to perform complementary annealing to form template DNA, and then through Overlapping PCR.
  • OverLAP overlapping overlapping
  • the nucleotide sequence shown in SEQ ID NO: 1 was synthesized. See Figure 1 for an overview of Overlapping PCR amplification.
  • the above preparation method can use primers (p-1 to p-16) of the nucleotide sequences shown in SEQ ID NOS: 2-17 and primers of the nucleotide sequences shown in SEQ ID NOS: 16-29, respectively ( Primers (p-27 to p-40) of the nucleotide sequences shown in SEQ ID NO: 28-41, which are p-15 to p-28), are synthesized to obtain three fragments, and the nucleus of SEQ ID NO: 2 is further used.
  • the primer (p-1) of the nucleotide sequence and the primer (p-40) of the nucleotide sequence shown by SEQ ID NO: 41 are amplified to form the entire DNA molecule.
  • the conditions of the Overlapping PCR method are: 98 ° C for 30 s, 58 ° C for 30 s, 72 ° C for 1 min, a total of 25 cycles, and finally 72 ° C for 7 min.
  • the reaction system is: p-1 (10 ⁇ /l) 1 ⁇ ⁇ - ⁇ (10 ⁇ / ⁇ ) 1 ⁇ ⁇ -2 to ⁇ - ( ⁇ -1) (1 ⁇ / ⁇ ) 1.5 ⁇ each
  • the DNA molecule of the present invention comprises the nucleotide sequence shown in SEQ ID NO: 1 and a 6 X His tag sequence, the 6 His tag sequence Located at the 5' end of the nucleotide sequence shown in SEQ ID NO: 1, the preparation method is as follows:
  • the primer of the acid sequence was subjected to PCR amplification to obtain a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 1 and the 6 X His tag sequence.
  • the PCR amplification conditions were: 95 ° C for 5 min, 94 ° C for 30 s, 50 ° C for 30 s, 72 ° C for 90 s, a total of 30 cycles, and finally 72 ° C lO min, 4 ° C incubation.
  • the present invention also provides a Pichia recombinant plasmid obtained by inserting a Pichia pastoris expression plasmid into a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 1.
  • the Pichia recombinant plasmid is obtained by inserting a DNA molecule comprising the nucleotide sequence of SEQ ID ⁇ : 1 and the 6 ⁇ His tag sequence between the Cpo I and Not I restriction sites by the pHBM-905A plasmid.
  • the 6 X His tag sequence is located at the 5th end of the nucleotide sequence shown in SEQ ID NO: 1. See Figure 2 for a schematic diagram of the construction of the Pichia pastoris recombinant plasmid of the present invention.
  • the present invention provides a Pichia pastoris recombinant engineering strain obtained by transforming any Pichia pastoris recombinant plasmid of the present invention into Pichia pastoris competent cells.
  • the Pichia pastoris recombinant engineering strain is obtained by electrophoresis into Pichia pastoris GS 115 competent cells by linearization of Pichia recombinant plasmid by Sal I digestion.
  • the Pichia pastoris recombinant plasmid of the present invention can successfully amplify a fragment having the same size and sequence as the nucleotide sequence shown in SEQ ID: 1 by SDS-PAGE electrophoresis, Western blotting and Mass spectrometry confirmed that the encoded amino acid sequence was consistent with the Pprl protein sequence of Radiation-resistant cocci, and the relative molecular mass was 43KD.
  • the Pichia pastoris recombinant engineering strain was induced by sterol, and the band of Pprl protein secretion was detected 24 hours after induction.
  • the final concentration of sterol is 1%
  • the temperature is 30 °C, pH 6.0
  • the highest expression of the target protein is 0.35 mg/ml at 120 h.
  • the present invention optimizes the transformation of the radiation-resistant cocci; pr/gene sequence under the premise of keeping the amino acid sequence of the Pprl protein unchanged, and encodes and synthesizes a new pprl gene, which can successfully construct the Pichia pastoris recombinant plasmid.
  • DRAWINGS Figure 1 shows a schematic diagram of Overlapping PCR amplification
  • Figure 2 is a schematic diagram showing the construction of a recombinant plasmid of Pichia pastoris
  • Figure 3 is a diagram showing the agarose gel electrophoresis of the DNA molecule, wherein Lane AB is Fragment 1, Fragment 2; Lane CJ is Fragment 3; Lane K-0 is the full-length Pi-pprl gene, and the arrow points to DNA.
  • Figure 4 is a diagram showing the agarose gel electrophoresis of the DNA molecule introduced into the 6 X His tag sequence, wherein 1 is a PCR amplification product, and M is a Maker;
  • Figure 5 is a PCR-assisted agarose gel electrophoresis map of the E. coli recombinant ⁇ -; ⁇ gene, wherein Lane A is a negative control, ie, no E. coli template after transformation; Lane BL is a transformed large intestine PCR product of bacillus as a template; Lane N is a PCR product using Pi-pprl gene as a template (positive control);
  • Figure 6 is a diagram showing the agarose gel electrophoresis of E. coli recombinant plasmid DNA, wherein Lane 1 is pHBM905A plasmid (negative control), the multiple-site filling fragment of the plasmid is 1200 bp; Lanes 2-12 are in Figure 5 a plasmid corresponding to a single colony of BL;
  • Figure 7 shows the ⁇ - ⁇ -/?/? ⁇ / and its Sal I restriction map, wherein Lane A is the recombinant plasmid ⁇ - ⁇ -/?/? ⁇ /; Lane BD is the recombinant plasmid ⁇ - ⁇ -/ ?/? ⁇ /Sal I digestion; Figure 8 shows the ⁇ - ⁇ -/?/? ⁇ /Pichia transformant PCR-tested agarose gel electrophoresis map, in which lane 1 is ⁇ 905 ⁇ plasmid as template PCR product (negative control); Lane 2 is the PCR product of the recombinant plasmid ⁇ - ⁇ -/?/? ⁇ / as a template (positive control); Lanes 3-16 are ⁇ - ⁇ -/?/? ⁇ /Pichia pastoris The transformant is a PCR product of the template;
  • Figure 9 shows the SDS-PAGE of induced expression of Pprl protein of ⁇ - ⁇ -/?;? ⁇ /Pichia pastoris, in which the lane control was pHBM905A Pichia pastoris transformant culture supernatant as a negative control; Lane 1 -7 is a culture supernatant of ⁇ - ⁇ -/?/? ⁇ /Pichia pastoris induced for 1-7 days, respectively, and the amount of each lane is 30 ul (equivalent to 24 ul culture supernatant); Lane M is Maker;
  • Figure 10 shows the detection of ⁇ - ⁇ -/? ⁇ /Pichia pastoris by Western Blot, where 1 is the first positive Pichia transformant induced 2 days of fermentation supernatant; 2 is the second positive Pichia The yeast transformant induced the fermentation supernatant for 2 days; 3 was the fermentation supernatant obtained by the first positive Pichia transformant for 1 day; M was Maker, and the loading amount was 16 ul of fermentation supernatant per lane;
  • Figure 11 shows the peptide mass fingerprint (PMF) of the ⁇ - ⁇ -/? ⁇ /Pichia transformant Ultraflex II TOF/TOF mass spectrometer. detailed description
  • the invention discloses a DNA molecule and a Pichia pastoris recombinant plasmid and a Pichia pastoris recombinant strain which efficiently expresses the P. aeruginosa Pprl protein, and those skilled in the art can learn from the contents of the present invention and appropriately improve the process parameters. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the present invention.
  • test materials used in the examples are as follows:
  • Escherichia coli strain E. coli XL10-GOLD and Pichia pastoris GS115 were purchased from Invitrogen, and Pichia pastoris expression vector pHBM-905A (8923 bp) was donated by Professor Ma Lixin of Hubei University (Ma Lixin, Zhao Xixuan, Chen Xiaoping, Li Zhaoxing, Fu Ling, Yao Yonglan. A method for efficiently constructing multiple copies of Pichia pastoris expression vector in vitro. Patent application number: 201210591987.X), see Figure 2 for plasmid expression.
  • Taq DNA polymerase, restriction endonuclease, T4 DNA ligase, etc. are all products of Dalian Baosheng Engineering Company. Both the plasmid DNA extraction kit and the DNA fragment gel recovery kit are products of Hangzhou Aisijin Biotechnology Co., Ltd.
  • the DNA molecular weight standard was purchased from Beijing Saibaisheng Co., Ltd.
  • the protein molecular weight standard was purchased from Bio-Rad.
  • the yeast basic nitrogen source (YNB) is a product of DIFCO.
  • the murine anti-His tag antibody is a product of SIGMA.
  • the HRP cross-linked rabbit anti-mouse antibody is a product of Invitrogen.
  • the ECL chemiluminescence kit was purchased from Millipore. Other reagents are domestic chemically pure or analytically pure products.
  • E. coli medium LB: 1% peptone, 0.5% yeast extract, l% NaCl, pH 7.0.
  • Yeast medium YPD plate (every 100ml double distilled water solution contains yeast extract lg, egg White peony 2g, glucose 2g, agar powder 2g), BMGY (containing 100g of yeast extract lg, peptone 2g, YNB 1.34g, 1ml of glycerol per 100ml of double-distilled aqueous solution), BMMY (containing lg, peptone per 100ml of double-distilled aqueous solution) 2g, 2g of glucose, 1ml of sterol), purchased from Shanghai Gensheng Biotechnology Co., Ltd.
  • the invention optimizes the open reading frame (ORF) sequence of the Deinococcus radiodurans Rl r/gene (DR 0167, Gene ID: 1798483) under the premise of keeping the amino acid sequence of the Pprl protein unchanged.
  • the present invention designs and synthesizes a series of overlapping (OVERLAP) primers of the nucleotide sequence shown in SEQ ID NO: 2-41 according to the artificially designed gene, and synthesizes the nucleoside comprising SEQ ID ⁇ : 1 by Overlapping PCR.
  • a DNA molecule with a Cpo I restriction endonuclease site and a Not I restriction endonuclease site for facilitating the construction of a subsequent recombinant plasmid.
  • the specific method is as follows:
  • the size of the DNA molecule was as expected by agarose gel electrophoresis, and the agarose gel electrophoresis pattern is shown in Fig. 3.
  • the conditions of the Overlapping PCR method were: 98 ° C for 30 s, 58 ° C for 30 s, 72 ° C for 1 min, a total of 25 cycles, and finally 72 ° C for 7 min.
  • the reaction system is (50 ⁇ ): P-1 (10 ⁇ / ⁇ )
  • Example 2 Synthesis of DNA molecule of the present invention (introduction of 6xffis tag sequence) The DNA molecule obtained in Example 1 was used as a template, and the nucleotide sequence shown in SEQ ID NO: 42 carrying the 6xffis tag sequence (CATCATCACCACCATCAT) was used.
  • the primer and the primer of the nucleotide sequence shown in SEQ ID NO: 41 were subjected to PCR amplification to obtain a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 1 and the 6xffis tag sequence (with a Cpo I restriction endonuclease site). Point, Not I restriction endonuclease site).
  • the primer SEQ ID NO: 42 introduces a 6 x ffis tag sequence based on the primer P-1.
  • the PCR amplification conditions were: pre-denaturation at 95 °C for 5 min, denaturation at 94 °C for 30 s, annealing at 50 °C for 30 s, extension at 72 °C for 90 s, a total of 30 cycles, and finally 72 extensions of 10111 ⁇ 1, 4 °C insulation. .
  • Pichia pastoris expression vector pHBM905A ( 8923 bp ) was digested with Cop I and Not I, and
  • the selected 11 transformant colonies were extracted with the AXYGEN microplasmid extraction kit for agarose gel electrophoresis, as shown in Fig. 6.
  • the results showed that 10 of the 11 transformants were recombinant plasmids of uniform molecular weight.
  • the Pi-pprK SEQ ID ⁇ : 1 nucleotide sequence) gene coding sequence of the present invention is designed and sequenced with the original Deinococcus radiodurans Rl pprl gene coding sequence (DR 0167, SEQ ID NO: 43 core) The nucleotide sequence) is completely different.
  • the bioinformatics software (www.bio-soft.net/sms/index.html) was used to analyze the Pi-pprl (nucleotide sequence shown in SEQ ID NO: 1) gene sequence, and the results showed that the encoded amino acid sequence and resistance were resistant.
  • the amino acid sequence of the Pprl protein (NP-293891.1) encoded by the pprl gene of De “ococc ⁇ radiodurans Rl” is completely identical (amino acid sequence is shown in SEQ ID NO: 44).
  • Pichia pastoris recombinant plasmid can be transformed into E. coli to propose a plasmid, the strip position is correct, the size is correct, and the sequencing result is Pz- ⁇ pr/ (SEQ ID ⁇ : 1
  • the nucleotide sequence of the nucleotide sequence is identical, and the gene sequence can correctly express the Pprl protein, indicating that the plasmid has been successfully constructed.
  • Example 5 Establishment of Pichia pastoris recombinant engineering bacteria
  • the correct Pichia pastoris recombinant plasmid pHBM-Pi-pprl was linearized by Sal I digestion.
  • Pichia pastoris competent cell preparation method was performed according to the Invitrogen operating manual (see www.pdffactory.com).
  • Pichia pastoris cells were coated with MD plates (MD: 1.34% YNB; 4x 10-5% biotin; 2% glucose), 28. After C culture for 2-3 days, the yeast transformant colonies on the MD plate were randomly picked for PCR identification. The primers used for the digestion of PCR were p-1 and p-40. The PCR results showed that the 987 b Pi-pprl (SEQ ID NO: 1 nucleotide sequence) gene sequence was amplified in 14 Pichia pastoris transformants (see Figure 8 for electrophoresis), indicating that the transformation was successful.
  • Example 6 Pichia pastoris recombinant engineering strain (pHBM-Pz- ⁇ pr/Pichia pastoris) induced expression of Pprl protein
  • the ⁇ - ⁇ -/?/? ⁇ /Pichia transformants which were identified as positive were picked and subjected to shake flask culture to induce expression.
  • the negative control strain was a transformant obtained by transforming the Pichia pastoris GS115 strain by the empty vector plasmid ⁇ -905 ⁇ linearized by Sal I. Methods as below:
  • Electrophoresis conditions 4% concentrated gel, 12% separation gel, Tris-Glycine Buffer (5 TGB 1L: Tris base 15.1 g, Glycine 94 g, SDS 5 g, dissolved in 800 ml dd3 ⁇ 40, and then fixed to volume To 1L).
  • the present invention randomly selects two positive pHBM- The sterol-induced culture supernatant of the Pz- ⁇ pr/ Pichia pastoris transformant was subjected to Western Blot assay, see Figure 10.
  • the present invention cuts off the separation on the SDS-PAGE electrophoresis gel of Example 6. Protein bands, Peptide Mass Fingerprinting (PMF) were detected with an Ultraflex II TOF/TOF mass spectrometer, and the results were imported into the National Center for Biotechnology Information (NCBI). The OMOSSA database is analyzed.
  • PMF Peptide Mass Fingerprinting
  • step 3 Repeat step 3 until the blue color fades.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

包含SEQ ID NO:1所示序列的DNA分子,及插入所述DNA分子的毕赤酵母重组质粒和转化所述毕赤酵母重组质粒到毕赤酵母感受态细胞并高效表达耐辐射球菌PprI蛋白的毕赤酵母重组菌。

Description

用于毕赤酵母重组质粒和表达耐辐射球菌 Pprl蛋白的毕赤酵母重组菌的 DNA分子 本申请要求于 2014 年 4 月 16 日提交中国专利局、 申请号为 201410153614.3、 发明名称为 "一种 DNA分子及毕赤酵母重组质粒和高 效表达耐辐射球菌 Pprl蛋白的毕赤酵母重组菌" 的中国专利申请的优先 权, 其全部内容通过引用结合在本申请中。 技术领域
本发明涉及生物技术领域, 具体涉及一种 DNA分子及毕赤酵母重组 质粒和高效表达耐辐射球菌 Pprl蛋白的毕赤酵母重组菌。
在核事故、核恐怖以及核战争等核突发事件中, 电离辐射可引起人体 严重的急性放射损伤 (acute radiation injury, ARI)。辐射损伤的救治与防护 关系到原子能的和平利用与国家核安全, 因此,该领域研究已成为世界各 国政府和学者高度关注与重点投入的研究领域。
耐辐射球菌 (Deinococcus radiodurans, DR )是迄今在地球上发现的 辐射抗性最强的原核细菌,该菌极强的抗辐射能力与其本身具有完善而高 效的 DNA修复系统有关,多种 DNA修复基因及其蛋白质对其特异的辐射 抗性起着至关重要的作用。 White等人于 1999年首次公布了 DR菌的基因序 歹' J , 其中促 DNA修复多效蛋白诱导因子 (inducer of pleiotropic proteins promoting DNA repair, ;?/?r/)是耐辐射球菌中一种具有重要调控作用的辐 射抗性基因, 它含有 987bp , 编码 328个 AA , 其产物 Pprl蛋白质是由 DR— 0167编码, 分子量为 37KD。 近年研究表明, pprl基因是耐辐射球菌控 制 DNA修复和保护途径的总开关基因,耐辐射球菌受照后 Pprl蛋白通过多 种信号通路调控 210多种基因的上调表达, 其中包括 21中与 DNA修复和复 制 相 关 的 基 因 【 H Lu, H Chen, G Xu, et al. DNA Repair,2012,l l(2): 139-145】。 耐辐射球菌发现 50余年来, 世界各国学者对 耐辐射球菌基因、蛋白质功能及其机理开展了深入细致的研究。 然而, 迄 今为止, 这些研究只局限于原核细胞内, 即耐辐射球菌自身或大肠杆菌。
申请号为 200910003512.2的中国专利首次构建了一种耐辐射球菌;? pr/ 基因的真核表达重组质粒 pCMV-HA-/?pr/,将其转入人胚肾 293T细胞和受 照哺乳动物体内, 成功表达了 Pprl蛋白质, 对动物致死性急性放射损伤具 有非常显著的防治作用,表明 Pprl蛋白质有望成为用于急性放射损伤防治 的一种新的生物制剂。 然而, 该专利真核表达重组质粒 pCMV-HA-/?pr/通 过人体细胞工程目前尚难以获得高效大量表达和纯化的 Pprl蛋白质。
应用原核表达系统大肠杆菌可高效表达和纯化 Pprl蛋白 【张永芹,周 辉, 陈洁,杨占山. 辐射研究与辐射工艺学报, 201 1 , 29(2): 1 17-122.】 , 然 而, 该种技术存在许多缺陷: 1. 表达的蛋白质没有经过糖基化等翻译后 修饰, 导致活性降低; 2. 表达的蛋白质以包涵体形式存在, 变性提取时 也会导致蛋白质活性降低; 3. 大肠杆菌本身内毒素和有毒蛋白可混杂在 目的蛋白产物中, 导致应用受限。
酵母是基因工程常用的真核表达系统之一, 其中巴斯德毕赤酵母
( Pichia pastoris )是以曱醇为唯一碳源的酵母工程菌的一种。 该酵母具 有如下优点, 1. 该酵母遗传操作简单, 基因组高度稳定, 可高水平表达 外源基因; 2. 能进行蛋白质翻译后的修饰行为, 如糖基化, 二硫键形成, 信号肽切除等; 3. 表达载体不含酵母复制原点, 外源基因同源重组到酵 母细胞染色体中稳定存在, 整合后的外源基因随酵母的生长可稳定传代。
如果能够通过真核表达系统毕赤酵母表达纯化耐辐射球菌 Pprl蛋白, 那么现有技术中通过人体细胞或原核表达系统大肠杆菌表达纯化 Pprl蛋 白的缺陷将会得到改善或解决。但是, 耐辐射球菌属于原核生物, 其与真 核生物毕赤酵母在种系进化上存在巨大差异,例如基因和蛋白质组成与功 能、蛋白质氨基酸密码子偏爱性等方面显著不同。 所以, 若直接将耐辐射 球菌 pprl基因通过基因工程构建到毕赤酵母表达系统中, 预实验研究证实 不可能并且也不利于高效表达耐辐射球菌 Pprl蛋白,按照本领域一般的基 因改造技术很难成功解决这一难题。 因此,本发明提供一种通过真核表达系统毕赤酵母成功表达纯化耐辐 射球菌( Deinococcus radiodurans Rl ) Pprl蛋白的技术, 为进一步研究该 蛋白质的功能、机制和应用奠定了厚实的基础,填补了国际辐射损伤救治 和防护领域尚无抗放原核蛋白质药物的空白,在辐射防护剂原创蛋白质药 物的研究跻身国际先进行列。 发明内容
有鉴于此, 本发明的目的是提供一种新合成的 DNA分子, 使得所述 DNA分子能够通过巴斯德毕赤酵母成功高效表达和纯化 Pprl蛋白。
此外, 本发明还提供同样能够实现发明目的的包含所述 DNA分子的 重组质粒和高效表达耐辐射球菌 Pprl蛋白的毕赤酵母重组菌。
为实现上述发明目的, 本发明提供如下技术方案:
一种 DNA分子, 其包含 SEQ ID NO: 1所示核苷酸序列。
本发明在保持 Pprl蛋白质氨基酸序列不变的前提下, 对耐辐射球菌 ( Deinococcus radiodurans Rl ) pprl基因 ( DR O 167 , Gene ID: 1798483 ) 开放阅读才匡 ( Open Reading Frame, ORF )序列进行优化改造, 编码合成新 的;? pr/基因, 即 SEQ ID NO: 1所示核苷酸序列, 为区别原有; ?pr/基因, 将 SEQ ID ΝΟ: 1所示核苷酸序列命名为 Pi-pprl 。
本发明所述包含 SEQ ID ΝΟ: 1所示核苷酸序列的 DNA分子是指在 SEQ ID NO: l所示核苷酸序列之外可以增加一些便于分离纯化蛋白诸如 6 His标签序列等序列, 本领域技术人员能够利用现有技术将这些不影响 Pi-pprl基因正常表达的序列与 Pi-pprl基因序列连接到一起, 这对于技术 人员来说是能够实现的。
此外,本领域技术人员可以根据实际要插入的质粒的酶切位点在所述 DNA分子的两端增加相对应的酶切位点, 也可以选择其他合适的标签序 列, 不仅限于本发明提到的 6 X His标签序列, 这些选择在本发明提供了 关键的 基因序列后均可以依靠现有技术实现, 同样未超出本发明 的核心技术范畴。
作为优选, SEQ ID ΝΟ: 1所示核苷酸序列由 SEQ ID NO:2-41所示核 苷酸序列的引物通过 Overlapping PCR扩增得到。 本发明利用 SEQ ID NO:2-41所示核苷酸序列的一系列互相重叠 (OVERLAP ) 引物 (以下简 称 p-1 至 p-40 ) 的重叠部分进行互补退火形成模板 DNA , 再通过 Overlapping PCR 方法合成得到 SEQ ID NO: 1 所示核苷酸序列。 Overlapping PCR扩增示意图参见图 1。
作为优选, 上述制备方法可分别用 SEQ ID NO:2-17所示核苷酸序列 的引物 ( p-1至 p-16 )、 SEQ ID NO: 16-29所示核苷酸序列的引物 ( p-15 至 p-28 ) 以及 SEQ ID NO:28-41所示核苷酸序列的引物 ( p-27至 p-40 ) 合成得到三个片段,进而再用 SEQ ID NO:2所示核苷酸序列的引物(p-1 ) 和 SEQ ID NO:41所示核苷酸序列的引物 ( p-40 )扩增形成整个 DNA分 子。
作为优选, 所述 Overlapping PCR方法合成的条件为: 98°C 30 s, 58 °C 30 s, 72 °C l min, 共 25个循环, 最后 72°C 7 min。 反应体系为: p-1 (10 μπιοΐ/l) 1 μΐ ρ-η (10 μπιοΐ/ΐ) 1 μΐ ρ-2至 ρ- (η-1)(1 μπιοΐ/ΐ) 各 1.5 μΐ
5 xPrimeSTAR® Buffer 10 μΐ dNTPs (2.5 mmol/1) 4 μΐ
PrimeSTAR® HS DNA Polymerase 0.5 μΐ ddH20 加至总体积 50 μΐ 作为优选,本发明所述 DNA分子包含 SEQ ID NO:l所示核苷酸序列 和 6 X His标签序列 ,所述 6 His标签序列位于 SEQ ID ΝΟ:1所示核苷酸 序列的 5' 端, 其制备方法如下:
以包含 SEQ ID ΝΟ:1所示核苷酸序列的 DNA分子为模板,利用带有 6 ffis 标签序列的 SEQ ID NO:42 所示核苷酸序列的引物和 SEQ ID NO:41所示核苷酸序列的引物进行 PCR扩增, 得到包含 SEQ ID NO:l所 示核苷酸序列和 6 X His标签序列的 DNA分子。
所述 PCR扩增条件为: 95°C 5 min, 94 °C 30 s, 50 °C 30 s, 72°C90 s, 共进行 30次循环, 最后 72 °C lO min, 4°C保温。 同时,本发明还提供一种毕赤酵母重组质粒, 由毕赤酵母表达质粒插 入包含 SEQ ID ΝΟ: 1所示核苷酸序列的 DNA分子获得。
作为优选, 所述毕赤酵母重组质粒由 pHBM-905A质粒在 Cpo I和 Not I酶切位点间插入包含 SEQ ID ΝΟ: 1所示核苷酸序列和 6 χ His标签 序列组成的 DNA分子获得, 所述 6 X His标签序列位于 SEQ ID NO: 1所 示核苷酸序列的 5, 端。 本发明所述毕赤酵母重组质粒构建示意图参见图 2。
此外,本发明还提供一种毕赤酵母重组工程菌, 由本发明任意一种毕 赤酵母重组质粒转化到毕赤酵母感受态细胞中获得。
作为优选, 所述毕赤酵母重组工程菌由毕赤酵母重组质粒经 Sal I酶 切线性化后, 电转化到毕赤酵母 GS 115感受态细胞中获得。
经凝胶电泳检测和测序,本发明所述毕赤酵母重组质粒能够成功扩增 出大小和序列与 SEQ ID ΝΟ: 1 所示核苷酸序列一致的片段, 利用 SDS-PAGE 电泳、 Western blotting和质谱检测, 证实其编码的氨基酸序 列与耐辐射球菌的 Pprl蛋白序列一致, 相对分子质量为 43KD。 同时, 所 述毕赤酵母重组工程菌经过曱醇诱导表达, 在诱导 24 h即可检出 Pprl蛋 白分泌表达的条带。 作为优选, 在诱导蛋白表达时曱醇终浓度为 1% , 温 度 30 °C , pH6.0 , 诱导 120h时目的蛋白表达量最高, 为 0.35mg/ml。 以上 检测试验结果表明, 本发明所提供的 DNA分子、 毕赤酵母重组质粒以及 毕赤酵母重组工程菌能够成功地在毕赤酵母中分泌表达 Pprl蛋白, 也就 证明其能够应用于制备毕赤酵母重组质粒、毕赤酵母重组工程菌以及抗辐 射损伤药物中。
由以上技术方案可知, 本发明在保持 Pprl蛋白质氨基酸序列不变的 前提下,对耐辐射球菌;?pr/基因序列进行优化改造,编码合成了新的 pprl 基因,能够成功构建毕赤酵母重组质粒和毕赤酵母重组工程菌,并分泌表 达 Pprl蛋白, 为进一步利用酵母发酵系统大量高效制备抗辐射损伤蛋白 质药物奠定了坚实的基础。 附图说明 图 1所示为 Overlapping PCR扩增示意图;
图 2所示为毕赤酵母重组质粒构建示意图;
图 3所示为所述 DNA分子琼脂糖凝胶电泳图,其中泳道 A-B为片段 1、 片段 2; 泳道 C-J为片段 3 ; 泳道 K-0为全长 Pi-pprl基因, 箭头所指 处为 DNA分子量标准条带的大小 (bp );
图 4所示为引入 6 X His标签序列的所述 DNA分子琼脂糖凝胶电泳 图, 其中 1为 PCR扩增产物, M为 Maker;
图 5所示为大肠杆菌重组子 ΡΖ-;^ΓΙ基因的 PCR验证琼脂糖凝胶电泳 图, 其中泳道 A为阴性对照, 即不加转化后的大肠杆菌模板; 泳道 B-L 为以转化后的大肠杆菌为模板的 PCR产物; 泳道 N为以 Pi-pprl的基因 为模板的 PCR产物 (阳性对照);
图 6所示为大肠杆菌重组子质粒 DNA的琼脂糖凝胶电泳图, 其中泳 道 1为 pHBM905A质粒(阴性对照 ), 该质粒的多克隆位点填充片段为 1200bp; 泳道 2-12为图 5中 B-L对应的单菌落的质粒;
图 7所示为 ρΗΒΜ-Ρ -/?/?Γ/及其 Sal I酶切图, 其中泳道 A为重组质 粒 ρΗΒΜ-Ρ -/?/?Γ/; 泳道 B-D为重组质粒 ρΗΒΜ-Ρ -/?/?Γ/经 Sal I酶切图; 图 8所示为 ρΗΒΜ-Ρ -/?/?Γ/毕赤酵母转化子 PCR验证琼脂糖凝胶电泳 图, 其中泳道 1为 ρΗΒΜ905Α质粒为模板的 PCR产物 (阴性对照); 泳 道 2为重组质粒 ρΗΒΜ-Ρ -/?/?Γ/为模板的 PCR产物(阳性对照);泳道 3-16 为 ρΗΒΜ-Ρ -/?/?Γ/毕赤酵母转化子为模板的 PCR产物;
图 9 所示为 ρΗΒΜ-Ρ -/?;?Γ/毕赤酵母转化子 Pprl蛋白的诱导表达 SDS-PAGE图, 其中泳道对照为 pHBM905A毕赤酵母转化子培养上清液 作为阴性对照; 泳道 1-7为分别诱导 1-7天的 ρΗΒΜ-Ρ -/?/?Γ/毕赤酵母转 化子培养上清液, 每个泳道上样量为 30 ul (相当于 24 ul培养上清液); 泳道 M为 Maker;
图 10所示为 ρΗΒΜ-Ρ -/?ρΓ/毕赤酵母转化子 Western Blot检测,其中 1为第一个阳性毕赤酵母转化子诱导 2天的发酵上清; 2为第二个阳性毕 赤酵母转化子诱导 2天的发酵上清; 3为第一个阳性毕赤酵母转化子诱导 1天的发酵上清; M为 Maker, 上样量为每泳道 16ul发酵上清; 图 11所示为 ρΗΒΜ-Ρ -/?ρΓ/毕赤酵母转化子 Ultraflex II TOF/TOF质 谱仪的肽质量指紋图谱(PMF )。 具体实施方式
本发明公开了一种 DNA分子及毕赤酵母重组质粒和高效表达耐辐射 球菌 Pprl蛋白的毕赤酵母重组菌, 本领域技术人员可以借鉴本文内容, 适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本 领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的 DNA分子、 赤酵母重组质粒和毕赤酵母重组菌已经通过较佳实施例进行 了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述 的方法和应用进行改动或适当变更与组合, 来实现和应用本发明技术。
实施例中所用试验材料如下:
1、 菌株与质粒
大肠杆菌菌株 E. coli XL10-GOLD 和巴斯德毕赤酵母菌株 (Pichia pastoris) GS115购自 Invitrogen公司,毕赤酵母表达载体 pHBM-905A( 8923 bp )由湖北大学马立新教授惠赠(马立新, 赵西选, 陈晚苹, 李晔星, 付 玲, 姚永兰。 一种离体高效构建多拷贝毕赤酵母表达载体的方法。 专利申 请号: 201210591987.X ), 质粒图语参见图 2。
2、 试剂和培养基
Taq DNA聚合酶、 限制性内切酶、 T4 DNA连接酶等均为大连宝生 物工程公司产品。 质粒 DNA提取试剂盒和 DNA片段凝胶回收试剂盒均 为杭州爱思进生物技术公司产品。 DNA分子量标准购自北京赛百盛公 司。蛋白分子量标准购自 Bio-Rad公司。 酵母基础氮源( YNB )为 DIFCO 公司产品。 鼠源 anti-His tag抗体为 SIGMA公司产品。 HRP交联的兔抗 鼠抗体为 Invitrogen公司产品。 ECL化学发光试剂盒购自 Millipore公司。 其他试剂均为国产化学纯或分析纯产品。
大肠杆菌培养基: LB: 1%蛋白胨, 0.5% 酵母提取物, l% NaCl , pH 7.0。
酵母培养基: YPD平板(每 100ml双蒸水溶液含酵母提取物 lg、 蛋 白胨 2g、 葡萄糖 2g、 琼脂粉 2g ), BMGY (每 100ml双蒸水溶液含酵母 提取物 lg、 蛋白胨 2g、 YNB 1.34g、 甘油 1ml ), BMMY (每 100ml双蒸 水溶液含酵母提取物 lg、 蛋白胨 2g、 葡萄糖 2g、 曱醇 lml ), 购自上海 根生生物科技公司。
下面结合实施例, 进一步阐述本发明。 实施例 1: 本发明所述 DNA分子的优化和合成
本发明在保持 Pprl蛋白质氨基酸序列不变的前提下, 对耐辐射球菌 ( Deinococcus radiodurans Rl ) r/基因 ( DR 0167 , Gene ID: 1798483 ) 开放阅读框( Open Reading Frame, ORF )序列进行优化改造, 编码合成了 新的 pprl基因—Pi-pprl基因, 即 SEQ ID NO: 1所示核苷酸序列, 以期高 效表达目的蛋白。
1、 合成方法
本发明根据人工设计的 基因,设计并合成了 SEQ ID NO:2-41 所示核苷酸序列的一系列互相重叠( OVERLAP )引物, 通过 Overlapping PCR合成得到包含 SEQ ID ΝΟ: 1所示核苷酸序列并带有 Cpo I限制性内 切酶位点和 Not I限制性内切酶位点 (便于后续重组质粒的构建)的 DNA 分子。 具体方法如下:
分别用 SEQ ID NO:2-17所述核苷酸序列的引物( p-1至 p-16 , 404bp )、 SEQ ID NO: 16-29所述核苷酸序列的引物( p-15至 p-28 , 370bp )以及 SEQ ID NO:28-41 所述核苷酸序列的引物 (p-27 至 p-40 , 330bp ) 进行 Overlapping PCR合成得到三个片段, 依次为片段 1、 片段 2和片段 3。
三个片段合成后, 以这三个片段为模板, 用 SEQ ID NO:2所示核苷 酸序列的引物 ( -1 )和 SEQ ID NO:41所示核苷酸序列的引物 ( p-40 )扩 增形成整个 DNA分子。
经琼脂糖凝胶电泳检测, 所述 DNA分子大小与预期一致, 琼脂糖凝 胶电泳图参见图 3。
其中, Overlapping PCR方法合成的条件为: 98°C 30 s, 58 °C 30 s, 72 °C 1 min, 共 25个循环, 最后 72 °C 7 min。 反应体系为(50 μΐ): p-1 (10 μπιοΐ/ΐ)
p-n (10 μπιοΐ/ΐ)
p-2至 p- (n-l)(l μπιοΐ/ΐ) 各 1.5 μ1
PrimeSTAR® Buffer 10 μΐ dNTPs (2.5 mmol/1) 4μ1
PrimeSTAR® HS DNA Polymerase 0.5 μΐ ddH20 加至总体积 50 μΐ
PCR扩增条件为: 95°C预变性 5min, 94°C变性 30 s, 50°C退火 30 s, 72 °C延伸 90s, 共进行 30次循环, 最后 72 延伸 10111^1, 4°C保温。 实施例 2: 本发明所述 DNA分子 (引入 6xffis标签序列) 的合成 以实施例 1 得到的 DNA 分子为模板, 用带有 6xffis 标签序列 ( CATCATCACCACCATCAT ) 的 SEQ ID NO:42所示核苷酸序列的引物 和 SEQIDNO:41所示核苷酸序列的引物进行 PCR扩增便得包含 SEQ ID ΝΟ:1所示核苷酸序列和 6xffis标签序列的 DNA分子 (带有 Cpo I限制 性内切酶位点、 Not I限制性内切酶位点 )。 其中, 引物 SEQ ID NO:42即 在引物 P- 1基础上引入 6 xffis标签序列。
PCR扩增条件为: 95°C预变性 5min, 94°C变性 30 s, 50°C退火 30 s, 72 °C延伸 90s, 共进行 30次循环, 最后 72 延伸 10111^1, 4°C保温。
取 3μ1 PCR扩增产物用 0.8%琼脂糖凝胶电泳检测,结果表明 PCR扩 增产物的大小(1005 bp)与预期一致, 琼脂糖凝胶电泳图参见图 4。 实施例 3: 毕赤酵母重组质粒的构建
将毕赤酵母表达载体 pHBM905A( 8923 bp )用 Cop I和 Not I双酶切, 经琼
Figure imgf000010_0001
DNA聚合酶处理, 然后与割胶回收大片段进行连接, 获得毕赤酵母重组 表达质粒 ρΗΒΜ-905Α-Ρ-/?/?Γ/ ( 8706 bp ), 简称 ρΗΒΜ-Ρ-/?/?Γ/, 构建流程 图示于图 2。 实施例 4: 大肠杆菌转化子的鉴定
为了验证所构建的毕赤酵母重组质粒是否成功构建,将其转化至大肠 杆菌中, 然后进行鉴定。
1、 煮菌 PCR鉴定
从大肠杆菌转化平板上随机挑选 11个转化子菌落, 分别转接入装有 20μ1无菌水的 1.5 ml Eppendorf管中, 置于沸水浴 3分钟, 水浴冷却。 高 速离心( 14,000 rpm ) 1 min。 取上清 1-2μ1为模板, 用引物 ρ-1和 ρ-40进 行 PCR扩增反应。 将 PCR反应产物进行琼脂糖凝胶电泳检查, 见图 5。 结果显示 11个转化子中有 10个转化子都能得到实施例 2所合成的基因。
2、 转化子质粒 DNA的琼脂糖凝胶电泳
将挑选的 11个转化子菌落用 AXYGEN微量质粒抽提试剂盒提取质 粒 DNA, 进行琼脂糖凝胶电泳检查, 见图 6。 结果显示, 11个转化子中 有 10个为分子量大小一致的重组质粒。
3、 转化子质粒 DNA的测序鉴定
随机挑取 3个经菌落 PCR鉴定和质粒大小比对正确的重组质粒进行 测序。 结果表明, 插入的 pprl基因编码序列与人工设计合成的 SEQ ID ΝΟ: 1所示核苷酸序列完全一致。本发明设计合成的 Pi-pprK SEQ ID ΝΟ: 1 所示核苷酸序列 ) 基因编码序列与原有耐辐射球菌(Deinococcus radiodurans Rl ) pprl基因编码序列 ( DR 0167 , SEQ ID NO:43所示核苷 酸序列 ) 完全不同。
4、 生物信息学软件分析结果
利用生物信息学软件 ( www.bio-soft.net/sms/index.html )分析 Pi-pprl ( SEQ ID ΝΟ: 1所示核苷酸序列)基因序列, 结果表明, 其编码的氨基酸 序列与耐辐射球菌 (De "ococc^ radiodurans Rl ) pprl基因编码的 Pprl蛋 白 (NP— 293891.1)的氨基酸序列完全一致(氨基酸序列如 SEQ ID NO:44所 示)。
由上述检测结果可知, 毕赤酵母重组质粒转化大肠杆菌能够提出质 粒, 条带位置正确、 大小正确, 且测序结果与 Pz-^pr/ ( SEQ ID ΝΟ: 1所 示核苷酸序列)基因序列一致, 基因序列能够正确表达 Pprl蛋白, 说明该质粒已经构建成功。 实施例 5: 毕赤酵母重组工程菌的建立
将鉴定正确的毕赤酵母重组质粒 pHBM-Pi-pprl经 Sal I酶切线性化后
(电泳图见图 7 ), 电转化毕赤酵母 GS115感受态细胞, 获得毕赤酵母重 组工程菌(pHBM-Pz-^pr/毕赤酵母转化子)。 毕赤酵母感受态细胞制备方 法按照 Invitrogen公司的操作手册进行 (见 www.pdffactory.com )。
电转化实验的相关参数分别为: Voltage Booster: 4 kQ , Capacitance: 50 μΈ , DC VOLTS: 410 , Charge Rate: Fast。
将电转化后的毕赤酵母细胞涂布 MD 平板(MD : 1.34% YNB ;; 4x 10-5% 生物素; 2%葡萄糖), 28。C培养 2-3天后, 随机挑取 MD平板 上的酵母转化子菌落进行煮菌 PCR鉴定。 煮菌 PCR釆用的引物为 p-1和 p-40。 PCR结果显示 14个毕赤酵母转化子中都能扩增出 987 b 的 Pi-pprl ( SEQ ID ΝΟ: 1所示核苷酸序列)基因序列 (电泳图见图 8 ), 表明转化 成功。 实施例 6: 毕赤酵母重组工程菌 (pHBM-Pz-^pr/毕赤酵母转化子) Pprl蛋白的诱导表达
挑取经鉴定为阳性的 ρΗΒΜ-Ρ -/?/?Γ/毕赤酵母转化子, 进行摇瓶培养 诱导表达。 阴性对照菌株为空载体质粒 ρΗΒΜ-905Α经 Sal I酶切线性化 后转化毕赤酵母 GS115菌株获得的转化子。 方法如下:
(1)挑取一个 ρΗΒΜ-Ρ -/?/?Γ/毕赤酵母转化子单菌落, 接种至 50 ml BMGY液体培养基中(按 10%装瓶,即 50 ml培养基装在 500 ml培养瓶中), 在 28 -30°C摇床中培养, 摇床转速为 250-300 rpm , 当菌体生长至 OD600=20-30时收获;
(2) 室温离心 5,000 rpm , 5 min , 去除上清, 收集细胞, 用 50 ml BMMY(BMMY: 2%蛋白胨, 1% 酵母提取物, 1%硫酸铵, 0.34% YNB , 100 mmol/L PBS H 6.0 ; ) 重新悬浮细胞,在 28-30°C摇床中继续培养,摇床转速为 250-300 rpm;
(3)每隔 24 h, 向摇瓶中加入曱醇至终浓度为 1%进行诱导表达;
(4)在下列的各个时间点 (24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168h) 取 1 ml培养液至 1.5 ml离心管, 室温离心 5,000 rpm, 5 min, 收集上清 液保存 4°C水箱备用。
(5)待连续培养 7天的样品都收齐之后,将每个时间点的样品各取 40 ul培养上清液分别转入新的 1.5 ml Eppendorf管中, 各加入 10 ul蛋白样 品处理液( 5xSDS-PAGE Loading buffer 100ml: lmol/L Tris-HCl H 6.8 : 25 ml; 甘油: 50 ml; SDS: 10 g ; 溴酚蓝: 0.5 g; 巯基乙醇: 5.0 ml ; 双蒸水: 定容至 100ml ), 混勾后置于沸水浴中变性 10 min。 每个样品各 取用 30 ul上样进行 SDS-PAGE电泳观察表达情况。
(6) 电泳条件:浓缩胶 4 % ,分离胶 12 % ,电泳液为 Tris-Glycine Buffer ( 5 TGB 1L: Tris base 15.1 g, Glycine 94 g, SDS 5 g,溶于 800 ml dd¾0, 再定容至 1L )。 染色液为考马斯亮蓝, 脱色液为 95%乙醇:水乙酸:水 = 4.5:0.5:5(V:V:V)。
结果显示, 诱导 24 h即可检出 Pprl蛋白分泌表达的条带, 随着诱导 时间的延长, Pprl蛋白表达量也逐渐增加, 至诱导到 120 h时表达量达到 最高,之后趋于稳定(电泳图见图 9 )。图中 Pprl蛋白的分子量约为 43kD, 提示该蛋白可能存在糖基化修饰。 实施例 7: 毕赤酵母重组工程菌 (pHBM-Pz-^pr/毕赤酵母转化子) 表达产物的 Western Blot检测
为了判断毕赤酵母重组工程菌 (ρΗΒΜ-Ρζ - r/毕赤酵母转化子)培 养上清液中的特异性表达蛋白是否确实为 6xffis-PprI 融合蛋白, 本发明 随机选取其中 2个阳性 pHBM-Pz-^pr/毕赤酵母转化子的曱醇诱导培养上 清液进行 Western Blot检测, 见图 10。 结果显示, 抗 6xffis的标签抗体能 与这 2个阳性 ρΗΒΜ-Ρ -/?/?Γ/毕赤酵母转化子培养清液中 43 kDa位置附 近的蛋白条带发生特异性结合反应,而且反应强度随曱醇诱导时间的增加 而相应增强 , 表明 pHBM-Pz - r/毕赤酵母转化子培养上清液中的特异 性蛋白为 6xffis-PprI融合蛋白。 实施例 8: 毕赤酵母重组工程菌 (pHBM-Pz-^pr/毕赤酵母转化子) 表达产物的质谱鉴定
为了进一步验证 pHBM-Pz-^r/毕赤酵母转化子表达上清液中的蛋白 是否为耐辐射球菌的 Pprl蛋白, 本发明割取了实施例 6中的 SDS-PAGE 电泳胶上分离的目的蛋白条带, 用 Ultraflex II TOF/TOF 质谱仪进行了肽 质量指紋图谱(Peptide Mass Fingerprinting, PMF ) 的检测, 并将检测结 果输入美国国家生物技术信息中心 (The National Center for Biotechnology Information, NCBI)的 OMOSSA数据库进行分析。
目的蛋白的处理方法:
1) 用切胶笔切下目的条带, 置于离心管中。
2) 用 50 μΐ双蒸水洗两次, 每次 10 min。
3)加 50 μΐ脱色液 (50mM NH4HC03 : CH3CN = 1:1), 37°C脱色 20 min。
4) 重复步骤 3 , 直至蓝色褪去。
5)加 50 μΐ CH3CN使胶条脱水至白色, 真空干燥 10 min。
6)加 10 mM DTT (13用 25mM NH4HC03配制) 50 μΐ, 56 °C水浴 1 h。
7) 样品冷至室温, 去除溶液, 快速加 30-40 mM IAA (用 25 mM 丽 4HC03配制) 50 μ1, 置于暗室 45 min。
8)依次用 25 mM NH4HCO3, 25 mM NH4HCO3+50% CH3CN各清洗 胶条两次,每次 lO min,再用 CH3CN脱水至胶条变白,真空干燥 10 min。
9)将 0.1 g l Trypsin液用 25 mM NH4HC03稀释 10-20倍, 每管加 2-3 μΐ, 短暂离心, 让酶液与胶条充分接触, 4 °C放置 30 min。 待酶解液 被完全吸收, 加 25 mM NH4HC03至总体积 10-15 μΐ, 37。C过夜。
10)加入 2 μΐ 0.1%TFA终止反应, 振荡混匀, 离心收集酶解液, 点 靶。 肽质量指紋图谱 (Peptide Mass Fingerprinting, PMF)分析, 检测肽段的分 子量(m/z, z为一个单位正电荷) 范围在 900-4000范围内(见图 11)。 登陆美国国家生物信息中心网站( www.ncbi.nlm.nih.gov )的 NCBI nr 数据库, 选择物种为 bacteria, 对质谱测得的 PMF结果进行搜索分析。 结果显示, 该蛋白序列确实是来源于耐辐射球菌 ( Deinococcus radiodurans ) 的蛋白 (NP— 293891.1)。 表明含有 基因序列的毕赤酵 母重组工程菌成功分泌表达了耐辐射球菌 Pprl蛋白。 以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的 普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进 和润饰, 这些改进和润饰也应视为本发明的保护范围。
序 列 表
<110> 苏州大学张家港工业技术研究院
<120> 一种 DNA分子及毕赤酵母重组质粒和高效表达耐辐射球菌 Pprl 蛋白的毕赤酵母重组菌
<130> OP140354
<160> 42
<170> Patentln version 3.3
<210> 1
<211> 987
<212> DNA
<213> 人工合成 <400> 1
atgccatctg ctaacgtttc tccaccatgt ccaagtggtg ttagaggcgg tggcatgggt 60 cctaaagcta aggcagaggc ttctaagcca catcctcaga taccagtaaa gttgccattt 120 gttactgcac cagatgcttt ggccgctgct aaagccagaa tgcgtgattt ggctgccgct 180 tatgtagcag cattgccagg tagagatact cattctttga tggctggtgt gccaggagtt 240 gatttgaagt ttatgccatt gggttggagg gatggtgcat ttgatccaga acataacgta 300 attctgatta acagtgcagc tagacctgaa agacaaagat ttacattggc tcatgaaatc 360 ggacatgcta ttttgttggg tgatgatgat ttgttgtccg atattcatga tgcttacgaa 420 ggtgagagat tggaacaagt tattgaaact ttgtgtaatg ttgccgcagc agccatactg 480 atgccagaac cagttatagc cgaaatgttg gaaagattcg gtccaactgg tagagcattg 540 gcagaattgg ctaagagagc agaagttagt gcttcctctg ctttgtacgc tttgactgaa 600 caaacaccag tacctgttat ctacgctgtt tgtgctccag gtaagcctcc aagagaacaa 660 gcagcttccg acgaagatgc cggtccatct actgaaaagg ttttaactgt tagggcctct 720 tcttccacta gaggtgttaa gtacactctt gcttctggta ctccagttcc agctgatcat 780 cctgcagcct tggcattagc tacgggtatg gaagtcagag aagagtctta cgttccattt 840 agatctggta ggaaaatgaa ggctgaagtt gatgcatacc catctagagg aattgttgca 900 gtttcttttg aatttgaccc agccagattg ggtagaaagg attctgagca ggctgataga 960 gatgaaccac aagatgctgc ccaataa 987
<210> 2
<211> 30
<212> DNA
<213> 人工合成
<400> 2
gtcagttcca tctgctaacg tttctccacc
30
<210> 3
Figure imgf000018_0001
ggggg ggg ggctcattcctaaactaa
gggggggggg ttaaa acttaca ataa
21146 <>
Figure imgf000019_0001
V ΑΐN>
Figure imgf000020_0001
^
o
0ΐ00 < V
Figure imgf000021_0001
46
Figure imgf000022_0001
^ 21014 <> 9 οΐ
Figure imgf000023_0001
β
V ΑΐN> § 0068ζ-<:/:ιοζζ>1£U IS8SSS OZAV
VN Αΐζν
Figure imgf000024_0001
Figure imgf000024_0002
91¾llmSIS ΒΟΒ ΟΛΛΟΜΜΟΜ oBogsc SSBBB 寒3/: Ϊ1£ s
Οΐ
Figure imgf000025_0001
9ΐΐ <ν
46
Figure imgf000026_0001
46 21025 <> L00寸 <〉
Figure imgf000027_0001
V
Figure imgf000027_0002
V
Figure imgf000027_0003
00寸 < V
9寸ΐΐζ Λν <213>
<400〉 ggtccat ctgaaaaggt tttaactgtt agggcctctt cttcca
Figure imgf000028_0001
<212> DNA
<213> 人工合成
Figure imgf000028_0002
<400> 31 aagcaagagt gtacttaaca cctctagtgg aagaagaggc cctaac 46
gggg caaaaa tcttac 46
Figure imgf000029_0001
gggggg ggg caatatc actaactata
21033 <>
g atcaacttcaccttc
Figure imgf000030_0001
gggggctaatt atcat 46
O gggggg ttcctacca atctaaat aactaaac tcttctcta cttcca 46
40035 Λ>
Figure imgf000031_0001
46
Figure imgf000031_0002
46
Figure imgf000032_0001
ggg caccaccatc atttccatc tctaactt tctccac gggggggcacatc tttttca
21041 <>

Claims

权 利 要 求
1、 一种 DNA分子, 其包含 SEQ ID NO: 1所示核苷酸序列。
2、 根据权利要求 1所述 DNA分子, 其特征在于, SEQ ID NO: l所 示核苷酸序列由 SEQ ID NO:2-41所示核苷酸序列的引物通过 Overlapping
PCR扩增得到。
3、根据权利要求 1所述 DNA分子, 其特征在于, 包含 SEQ ID NO: l 所示核苷酸序列和 6xffis标签序列, 所述 6xffis标签序列位于 SEQ ID ΝΟ: 1所示核苷酸序列的 5'端。
4、 权利要求 1-3任意一项所述 DNA分子在制备毕赤酵母重组质粒、 毕赤酵母重组工程菌以及抗辐射损伤药物中的应用。
5、 一种毕赤酵母重组质粒, 其特征在于, 由毕赤酵母表达质粒插入 包含 SEQ ID ΝΟ: 1所示核苷酸序列的 DNA分子获得。
6、 根据权利要求 5 所述毕赤酵母重组质粒, 其特征在于, 由 pHBM-905A质粒在 Cpo I和 Not I酶切位点间插入包含 SEQ ID NO: 1所 示核苷酸序列和 6xffis标签序列组成的 DNA分子获得, 所述 6xffis标签 序列位于 SEQ ID NO: l所示核苷酸序列的 5'端。
7、 权利要求 5或 6所述毕赤酵母重组质粒在制备毕赤酵母重组工程 菌以及抗辐射损伤药物中的应用。
8、 一种毕赤酵母重组工程菌, 其特征在于, 由权利要求 5或 6所述 毕赤酵母重组质粒转化到毕赤酵母感受态细胞中获得。
9、 根据权利要求 8所述毕赤酵母重组工程菌, 其特征在于, 由权利 要求 5或 6所述毕赤酵母重组质粒经 Sal I酶切线性化后, 电转化到毕赤 酵母 GS115感受态细胞中获得。
10、权利要求 8或 9所述毕赤酵母重组工程菌在制备抗辐射损伤药物 中的应用。
PCT/CN2014/078900 2014-04-16 2014-05-30 用于毕赤酵母重组质粒和表达耐辐射球菌ppri蛋白的毕赤酵母重组菌的dna分子 Ceased WO2015158031A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/123,757 US10000761B2 (en) 2014-04-16 2014-05-30 DNA molecule used for recombinant Pichia plasmid and recombinant Pichia strain expressing PprI protein of Deinococcus radiodurans

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410153614.3A CN103937814A (zh) 2014-04-16 2014-04-16 一种DNA分子及毕赤酵母重组质粒和高效表达耐辐射球菌PprI蛋白的毕赤酵母重组菌
CN201410153614.3 2014-04-16

Publications (1)

Publication Number Publication Date
WO2015158031A1 true WO2015158031A1 (zh) 2015-10-22

Family

ID=51185686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/078900 Ceased WO2015158031A1 (zh) 2014-04-16 2014-05-30 用于毕赤酵母重组质粒和表达耐辐射球菌ppri蛋白的毕赤酵母重组菌的dna分子

Country Status (3)

Country Link
US (1) US10000761B2 (zh)
CN (1) CN103937814A (zh)
WO (1) WO2015158031A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119431549A (zh) * 2024-11-08 2025-02-14 南京医科大学 一种LTα1β2体外表达生产方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105267947A (zh) * 2015-11-03 2016-01-27 苏州大学 一种新的耐辐射球菌PprI蛋白的用途及药物
CN106929530B (zh) * 2015-12-31 2019-03-29 天津大学 一种提高酵母细胞对复合抑制剂耐受能力的方法
CN108396012B (zh) * 2018-02-06 2020-10-23 中国农业科学院生物技术研究所 单克隆抗体1DB4在检测IrrE转基因农作物中的应用
CN108396013B (zh) * 2018-02-06 2020-11-27 中国农业科学院生物技术研究所 一种检测全局调控因子IrrE蛋白及其转基因农作物的金标试纸条
CN110590939B (zh) * 2019-09-20 2024-02-02 广州暨南大学医药生物技术研究开发中心有限公司 一种利用基因工程获得重组人纤连蛋白的方法
CN114990044B (zh) * 2022-06-30 2024-04-23 浙江大学 一种降解高氯酸盐的抗辐射细菌的制备及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101492651A (zh) * 2009-01-07 2009-07-29 苏州大学 一种含有原核基因pprI的真核重组质粒及其用途
CN101671679A (zh) * 2009-04-30 2010-03-17 浙江大学 一种耐辐射球菌抗逆相关基因及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236933A1 (en) * 2010-03-24 2011-09-29 Soochow University RECOMBINANT EUKARYOTIC EXPRESSION PLASMID ENCODING pprI GENE OF DEINOCOCCUS RADIODURANS R1 AND ITS FUNCTIONS
US20130011909A1 (en) * 2011-06-30 2013-01-10 Texas Tech University System Methods and composition to enhance production of fully functional p-glycoprotein in pichia pastoris
CN103555749B (zh) 2012-12-29 2015-06-24 湖北大学 一种离体构建多拷贝毕赤酵母表达载体的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101492651A (zh) * 2009-01-07 2009-07-29 苏州大学 一种含有原核基因pprI的真核重组质粒及其用途
CN101671679A (zh) * 2009-04-30 2010-03-17 浙江大学 一种耐辐射球菌抗逆相关基因及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119431549A (zh) * 2024-11-08 2025-02-14 南京医科大学 一种LTα1β2体外表达生产方法

Also Published As

Publication number Publication date
US10000761B2 (en) 2018-06-19
CN103937814A (zh) 2014-07-23
US20170016009A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
WO2015158031A1 (zh) 用于毕赤酵母重组质粒和表达耐辐射球菌ppri蛋白的毕赤酵母重组菌的dna分子
Dong et al. A novel bicistronic expression system composed of the intraflagellar transport protein gene ift25 and FMDV 2A sequence directs robust nuclear gene expression in Chlamydomonas reinhardtii
WO2012037774A1 (zh) 多拷贝高效表达重组菌丝霉素的酵母菌
CN106967660A (zh) 一种生产复苏促进因子的基因工程菌及其应用
CN104560896B (zh) 一种在大肠杆菌中表达ms2假病毒颗粒的方法
CN107475298A (zh) cdtB基因过表达慢病毒载体及其构建方法和包含cdtB基因的慢病毒及其应用
CN104195152B (zh) 一种钙调磷酸酶催化亚基基因及其应用
CN101607081B (zh) 布鲁氏菌疫苗及疫苗用抗原蛋白的制备方法
CN109777807B (zh) 一种在线粒体中定位表达外源蛋白的方法
CN103993030A (zh) 一种大肠杆菌细胞内蛋白酶剪切融合蛋白的方法
CN114276417B (zh) 一种在植物正常生理条件下鉴定全基因组dna鸟嘌呤四联体位点的方法
CN110746496A (zh) 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用
CN110819649A (zh) 一种重组果胶甲酯酶PbrPME的体外表达方法及其编码基因与应用
CN104593401B (zh) 一种应用pCold载体表达可溶性广州管圆线虫galectin‑1蛋白的方法
CN104360059A (zh) 一种马秋波病毒非诊断性的免疫学检测方法
CN101864424B (zh) 重组4A β 15在毕赤氏酵母中的高效分泌表达及纯化方法
CN104672314B (zh) 一种重组古紫质4蛋白及其制备方法和应用
CN106834327A (zh) Patatin样磷脂酶Ⅲ的可溶性表达制备方法
CN103725706A (zh) 一种表达可溶性猪肠三叶肽的重组载体、构建方法、重组工程菌及其表达方法
CN103675296B (zh) 与转基因植物外源Bt蛋白相互作用的人类蛋白ANKHD1
WO2022041231A1 (zh) 一种可用于人原代细胞基因编辑的Cas9蛋白的制备方法
CN112391367A (zh) 一种可用于人原代细胞基因编辑的Cas9蛋白的制备方法
CN103525854A (zh) 高基因敲除效率的谢瓦氏曲霉间型变种工程菌株的构建方法
CN103146721A (zh) 酿酒酵母6-磷酸海藻糖合成酶基因及其表达载体和应用
CN116355940B (zh) 一种猪o型口蹄疫病毒结构蛋白vp1的表达载体及其构建方法和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14889368

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15123757

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14889368

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/03/2017)

122 Ep: pct application non-entry in european phase

Ref document number: 14889368

Country of ref document: EP

Kind code of ref document: A1